Sökning: onr:"swepub:oai:DiVA.org:uu-527983" >
A Randomized Phase ...
-
Tabernero, JosepVall dHebron Hosp Campus, Barcelona 08035, Spain.;IOB Quiron, Inst Oncol VHIO, Barcelona, Spain.;UV UCC, Inst Oncol VHIO, IOB Quiron, Barcelona 08035, Spain.
(författare)
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer : The AGENT Trial
- Artikel/kapitelEngelska2024
Förlag, utgivningsår, omfång ...
-
American Association For Cancer Research (AACR),2024
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-527983
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-527983URI
-
https://doi.org/10.1158/2767-9764.CRC-23-0361DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Purpose:Suboptimal treatment outcomes with 5-fluorouracil (5-FU)/folate, the standard of care for metastatic colorectal cancer (mCRC), have generated interest in optimizing the folate. Arfolitixorin ([6R]-5,10-methylene-tetrahydrofolate) is an immediately active folate and may improve outcomes over the existing standard of care (leucovorin).Experimental Design:AGENT was a randomized, phase III study (NCT03750786). Patients with mCRC were randomized to arfolitixorin (120 mg/m2 given as two intravenous bolus doses of 60 mg/m2) or leucovorin (400 mg/m2 given as a single intravenous infusion) plus 5-FU, oxaliplatin, and bevacizumab. Assessments were performed every 8 weeks. The primary endpoint was the superiority of arfolitixorin for overall response rate (ORR).Results:Between February 2019 and April 2021, 490 patients were randomized (245 to each arm). After a median follow-up of 266 days, the primary endpoint of superiority for ORR was not achieved (48.2% for arfolitixorin vs. 49.4% for leucovorin, Psuperiority = 0.57). Outcomes were not achieved for median progression-free survival (PFS; 12.8 and 11.6 months, P = 0.38), median duration of response (12.2 and 12.9 months, P = 0.40), and median overall survival (23.8 and 28.0 months, P = 0.78). The proportion of patients with an adverse event of grade ≥3 severity was similar between arms (68.7% and 67.2%, respectively), as was quality of life. BRAF mutations and MTHFD2 expression were both associated with a lower PFS with arfolitixorin.Conclusions:The study failed to demonstrate clinical benefit of arfolitixorin (120 mg/m2) over leucovorin. However, it provides some useful insights from the first-line treatment setting, including the effect of gene expression on outcomes.Significance:This phase III study compared arfolitixorin, a direct-acting folate, with leucovorin in FOLFOX plus bevacizumab in mCRC. Arfolitixorin (120 mg/m2) did not improve the ORR, potentially indicating a suboptimal dose.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Yoshino, TakayukiNatl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan.
(författare)
-
Stintzing, SebastianCharite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany.
(författare)
-
de Gramont, AimeryInst Hosp Franco Britannique, Oncol Med, Levallois Perret, France.
(författare)
-
Gibbs, PeterSunshine Hosp, Western Hlth, Med Oncol, St Albans, Vic, Australia.
(författare)
-
Jonker, Derek J.Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada.
(författare)
-
Nygren, PeterUppsala universitet,Cancerprecisionsmedicin(Swepub:uu)peterng
(författare)
-
Papadimitriou, ChristosNatl & Kapodistrian Univ Athens, Aretaieion Univ Hosp, Oncol Unit, Athens, Greece.
(författare)
-
Prager, Gerald W.Med Univ Wien, Vienna, Austria.
(författare)
-
Tell, RogerIsofol Med AB, Gothenburg, Sweden.
(författare)
-
Lenz, Heinz-JosefUniv Southern Calif, Keck Sch Med, Div Med Oncol & Colorectal Canc, Los Angeles, CA USA.
(författare)
-
Vall dHebron Hosp Campus, Barcelona 08035, Spain.;IOB Quiron, Inst Oncol VHIO, Barcelona, Spain.;UV UCC, Inst Oncol VHIO, IOB Quiron, Barcelona 08035, Spain.Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Cancer Research Communications: American Association For Cancer Research (AACR)4:1, s. 28-372767-9764
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Tabernero, Josep
-
Yoshino, Takayuk ...
-
Stintzing, Sebas ...
-
de Gramont, Aime ...
-
Gibbs, Peter
-
Jonker, Derek J.
-
visa fler...
-
Nygren, Peter
-
Papadimitriou, C ...
-
Prager, Gerald W ...
-
Tell, Roger
-
Lenz, Heinz-Jose ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Cancer Research ...
- Av lärosätet
-
Uppsala universitet